Risikoen i PCIB har blitt litt mindre.
PCI Biotech: Independent evaluation confirms early promising signs of efficacy in the phase I/II bile duct cancer study
The phase I part of the study has been completed with good tolerability and
promising early signs of efficacy. The independent evaluation of the radiology
data at six months from patients treated in cohort III and the expanded cohort
IV is now finalised. A total of seven patients had radiologically evaluable
cancer and four of these had objective tumour response, of which two were
2 CR er meget bra og vil nok vekke litt oppmerksomhet der ute.
"The patient numbers in our study are small, but the results suggest a
several fold increase in objective tumour response rate compared to the
landmark study for the current standard treatment, the so called ABC02
study, published in the New England Journal of Medicine in 2010."